Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
August 8, 2019
Ideon Science Park

EXINI Press Release

EXINI a fully owned subsidiary of Progenics Pharmaceuticals, entered into collaboration with the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), United States, on its AI research program.

EXINI Press Release

EXINI a fully owned subsidiary of Progenics Pharmaceuticals, entered into collaboration with the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), United States, on its AI research program.

EXINI announces collaboration with Veterans Affairs in United States on the AI Research Program for Medical Image Analysis

On July 25, 2019, EXINI a fully owned subsidiary of Progenics Pharmaceuticals, entered into collaboration with the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), United States, on its AI research program.

The collaborative program aims to apply machine learning to medical imaging modalities, enabling standardized, information-driven healthcare practices in prostate cancer. The project is the nation’s first collaborative effort to validate cutting-edge machine learning tools for improving treatment management of Veterans with prostate cancer. Read More here

PSMA-AI

PSMA-AI is the first software in development by EXINI tailored to Progenics’ imaging agent pipeline – 1404 and DCFPyL. The imaging agents attach to a protein called Prostate-Specific Membrane Antigen (PSMA) which is overexpressed on the surface of prostate cancer cells. The agents are labelled with a radioactive molecule detectable by nuclear medicine cameras and used in conjunction with co-registered anatomical images to provide anatomical context to the functional images.

Central to PSMA-AI is the automatic and quantitative computation of assessments used to detect, localize, quantify and stage both localized and advanced prostate cancer lesions. The technology is based on deep learning and convolutional neural networks that determine a detailed anatomical context from the anatomical images. This information is combined with information from the corresponding PSMA-targeted functional image to assess cancer prevalence and growth. The performance of assessments in hybrid images on patients with prostate cancer by human experts has been statistically validated to improve when provided with the additional information retrieved with PSMA-AI.

EXINI Diagnostics AB

EXINI Diagnostics AB was established in 1999 to commercialize AI methods for automated analysis of diagnostic images developed by a research group at Lund University. As a certified medical device manufacturer, EXINI has developed automated analysis platforms for cardiac, brain and bone scans. The company has always been innovative, developing web-based systems in the early 2000s. EXINIs most widely distributed platform is used to calculate the automated Bone Scan Index, which quantifies the bone tumour burden in patients with metastatic prostate cancer. This platform has been installed at about 1,000 hospitals worldwide. In 2015, EXINI was acquired by Progenics Pharmaceuticals Inc. for developing patient-centric AI technologies for PSMA-targeted theranostic agents.

exini.com

The post EXINI Press Release appeared first on Ideon Science Park.

Last updated:
August 8, 2019

Ideon Science Park

Ideon Science Park is one of the most exciting places in Europe, where the smartest minds in the world meet to develop the future.

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 15
223 63 Lund
Sweden

Send us mail

EXINI announces collaboration with Veterans Affairs in United States on the AI Research Program for Medical Image Analysis

On July 25, 2019, EXINI a fully owned subsidiary of Progenics Pharmaceuticals, entered into collaboration with the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), United States, on its AI research program.

The collaborative program aims to apply machine learning to medical imaging modalities, enabling standardized, information-driven healthcare practices in prostate cancer. The project is the nation’s first collaborative effort to validate cutting-edge machine learning tools for improving treatment management of Veterans with prostate cancer. Read More here

PSMA-AI

PSMA-AI is the first software in development by EXINI tailored to Progenics’ imaging agent pipeline – 1404 and DCFPyL. The imaging agents attach to a protein called Prostate-Specific Membrane Antigen (PSMA) which is overexpressed on the surface of prostate cancer cells. The agents are labelled with a radioactive molecule detectable by nuclear medicine cameras and used in conjunction with co-registered anatomical images to provide anatomical context to the functional images.

Central to PSMA-AI is the automatic and quantitative computation of assessments used to detect, localize, quantify and stage both localized and advanced prostate cancer lesions. The technology is based on deep learning and convolutional neural networks that determine a detailed anatomical context from the anatomical images. This information is combined with information from the corresponding PSMA-targeted functional image to assess cancer prevalence and growth. The performance of assessments in hybrid images on patients with prostate cancer by human experts has been statistically validated to improve when provided with the additional information retrieved with PSMA-AI.

EXINI Diagnostics AB

EXINI Diagnostics AB was established in 1999 to commercialize AI methods for automated analysis of diagnostic images developed by a research group at Lund University. As a certified medical device manufacturer, EXINI has developed automated analysis platforms for cardiac, brain and bone scans. The company has always been innovative, developing web-based systems in the early 2000s. EXINIs most widely distributed platform is used to calculate the automated Bone Scan Index, which quantifies the bone tumour burden in patients with metastatic prostate cancer. This platform has been installed at about 1,000 hospitals worldwide. In 2015, EXINI was acquired by Progenics Pharmaceuticals Inc. for developing patient-centric AI technologies for PSMA-targeted theranostic agents.

exini.com

The post EXINI Press Release appeared first on Ideon Science Park.

Last updated:
August 8, 2019

Ideon Science Park

Ideon Science Park is one of the most exciting places in Europe, where the smartest minds in the world meet to develop the future.

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 15
223 63 Lund
Sweden

Send us mail